Literature DB >> 7769125

Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo.

J de la Mata1, H L Uy, T A Guise, B Story, B F Boyce, G R Mundy, G D Roodman.   

Abstract

Tumors frequently induce the multifunctional cytokine IL-6, which has been linked to several paraneoplastic syndromes, most notably cachexia. IL-6 stimulates osteoclast formation, causes mild hypercalcemia, and is produced by bone cells in vitro upon exposure to systemic hormones. Since IL-6 is produced together with parathyroid hormone-related protein (PTH-rP) in some patients with cancer, we tested the hypothesis that production of IL-6 potentiates the effects of PTH-rP on Ca2+ homeostasis and osteoclastic bone resorption and examined potential mechanisms for these interactions in vivo. Chinese hamster ovarian (CHO) cells stably transfected with cDNAs for IL-6 (CHO/IL-6) and PTH-rP sense (CHO/PTH-rP) or antisense (CHO/PTH-rP AS) were inoculated intramuscularly into nude mice. Experimental groups included CHO/IL-6 plus CHO/PTH-rP; CHO/IL-6 plus CHO/PTH-rP AS; CHO/IL-6 alone; and CHO/PTH-rP alone. Blood ionized Ca2+ was measured on days 0, 7, 10, 12, and 13. Three different developmental stages in the osteoclast lineage were examined at day 13: the early multipotential precursor, granulocyte macrophage colony-forming units (CFU-GM); more mature mononuclear osteoclast precursors, assessed by their capacity to form tartrate-resistant acid phosphatase-positive multinucleated cells in marrow cultures; and mature osteoclasts, assessed by histomorphometry. IL-6 increased CFU-GM but not bone resorption or Ca2+. In contrast, PTH-rP induced hypercalcemia and bone resorption and increased multinucleated osteoclasts and more mature precursors cells, but not CFU-GM. However, mice treated with both IL-6 and PTH-rP had very marked hypercalcemia and osteoclastosis as well as an increase in the number of both CFU-GM and mature osteoclast precursors. These data demonstrate that IL-6 enhances PTH-rP-mediated hypercalcemia and bone resorption, most likely by increasing the pool of early osteoclast precursors that in turn can differentiate to mature osteoclasts. We conclude that IL-6 stimulatory effects on osteoclast precursors may enhance the effects of other bone resorption factors that act at later stages in the osteoclast lineage.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7769125      PMCID: PMC295971          DOI: 10.1172/JCI117990

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  18 in total

1.  Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas.

Authors:  S Miki; M Iwano; Y Miki; M Yamamoto; B Tang; K Yokokawa; T Sonoda; T Hirano; T Kishimoto
Journal:  FEBS Lett       Date:  1989-07-03       Impact factor: 4.124

2.  Evidence for the involvement of interleukin 6 in experimental cancer cachexia.

Authors:  G Strassmann; M Fong; J S Kenney; C O Jacob
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

3.  Growth inhibition of human breast carcinoma and leukemia/lymphoma cell lines by recombinant interferon-beta 2.

Authors:  L Chen; Y Mory; A Zilberstein; M Revel
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

4.  Increased osteoclast development after estrogen loss: mediation by interleukin-6.

Authors:  R L Jilka; G Hangoc; G Girasole; G Passeri; D C Williams; J S Abrams; B Boyce; H Broxmeyer; S C Manolagas
Journal:  Science       Date:  1992-07-03       Impact factor: 47.728

5.  Effect of interleukin 6 (IL-6) on the differentiation and proliferation of murine and human hemopoietic progenitors.

Authors:  T Suda; Y Yamaguchi; J Suda; Y Miura; A Okano; Y Akiyama
Journal:  Exp Hematol       Date:  1988-12       Impact factor: 3.084

6.  Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides.

Authors:  F A Houssiau; J P Devogelaer; J Van Damme; C N de Deuxchaisnes; J Van Snick
Journal:  Arthritis Rheum       Date:  1988-06

7.  Modified immunoradiometric assay of parathyroid hormone-related protein: clinical application in the differential diagnosis of hypercalcemia.

Authors:  M R Pandian; C H Morgan; E Carlton; G V Segre
Journal:  Clin Chem       Date:  1992-02       Impact factor: 8.327

8.  Chinese hamster ovarian cells transfected with human parathyroid hormone-related protein cDNA cause hypercalcemia in nude mice.

Authors:  T A Guise; J M Chirgwin; G Favarato; B F Boyce; G R Mundy
Journal:  Lab Invest       Date:  1992-10       Impact factor: 5.662

9.  Neutralizing antibodies to human interleukin 6 reverse hypercalcemia associated with a human squamous carcinoma.

Authors:  T Yoneda; M Nakai; K Moriyama; L Scott; N Ida; T Kunitomo; G R Mundy
Journal:  Cancer Res       Date:  1993-02-15       Impact factor: 12.701

Review 10.  Interleukin-6, a new target for therapy in multiple myeloma?

Authors:  M H van Oers; H C van Zaanen; H M Lokhorst
Journal:  Ann Hematol       Date:  1993-05       Impact factor: 3.673

View more
  49 in total

Review 1.  Hormonal regulation of physiological cell turnover and apoptosis.

Authors:  R D Medh; E B Thompson
Journal:  Cell Tissue Res       Date:  2000-07       Impact factor: 5.249

2.  Regulation of the gp80 and gp130 subunits of the IL-6 receptor by sex steroids in the murine bone marrow.

Authors:  S C Lin; T Yamate; Y Taguchi; V Z Borba; G Girasole; C A O'Brien; T Bellido; E Abe; S C Manolagas
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

Review 3.  Osteoblast responses to bacterial pathogens: a previously unappreciated role for bone-forming cells in host defense and disease progression.

Authors:  Ian Marriott
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 4.  Cytokines in the pathogenesis of osteoporosis.

Authors:  E Romas; T J Martin
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

5.  Three-dimensional (3D) culture of bone-derived human 786-O renal cell carcinoma retains relevant clinical characteristics of bone metastases.

Authors:  Tianhong Pan; Eliza L S Fong; Mariane Martinez; Daniel A Harrington; Sue-Hwa Lin; Mary C Farach-Carson; Robert L Satcher
Journal:  Cancer Lett       Date:  2015-05-21       Impact factor: 8.679

6.  Suppression of bone resorption by madindoline A, a novel nonpeptide antagonist to gp130.

Authors:  Masahiko Hayashi; Mun-Chual Rho; Akiko Enomoto; Akiko Fukami; Yong-Pil Kim; Yuji Kikuchi; Toshiaki Sunazuka; Tomoyasu Hirose; Kanki Komiyama; Satoshi Omura
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-04       Impact factor: 11.205

7.  Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer.

Authors:  Ahmed Boucharaba; Claire-Marie Serre; Sandra Grès; Jean Sébastien Saulnier-Blache; Jean-Claude Bordet; Julien Guglielmi; Philippe Clézardin; Olivier Peyruchaud
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

8.  A small molecule, odanacatib, inhibits inflammation and bone loss caused by endodontic disease.

Authors:  Liang Hao; Wei Chen; Matthew McConnell; Zheng Zhu; Sheng Li; Michael Reddy; Paul D Eleazer; Min Wang; Yi-Ping Li
Journal:  Infect Immun       Date:  2015-01-12       Impact factor: 3.441

9.  Bone resorption caused by three periodontal pathogens in vivo in mice is mediated in part by prostaglandin.

Authors:  Y Zubery; C R Dunstan; B M Story; L Kesavalu; J L Ebersole; S C Holt; B F Boyce
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

Review 10.  [Postoperative and bacterial osteitis. New possibilities for therapy].

Authors:  V Heppert; U Glatzel; A Wentzensen
Journal:  Orthopade       Date:  2004-03       Impact factor: 1.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.